372-37-2

Basic information

• Product Name: ethylg-fluoroacetoacetate
• Synonyms: ethyl 4-fluoro-3-oxobutanoate;ethyl 4-fluoro-3-oxo-butanoate;Butanoic acid,4-fluoro-3-oxo-, ethyl ester;ethylg-fluoroacetoacetate;4-Fluoroacetoacetic acid ethyl ester;4-fluoro-3-keto-butyric acid ethyl ester
• CAS NO: 372-37-2
• Molecular Formula: C₆H₉FO₃
• Molecular Weight: 148.13
• Mol File: 372-37-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 178.5°Cat760mmHg
• Flash Point: 60.5°C
• Appearance: /
• Density: 1.108g/cm³
• PKA: 9.52±0.46(Predicted)
• CAS DataBase Reference: ethylg-fluoroacetoacetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethylg-fluoroacetoacetate(372-37-2)
• EPA Substance Registry System: ethylg-fluoroacetoacetate(372-37-2)

Safety Data

• Hazardous Substances Data: 372-37-2(Hazardous Substances Data)

Usage

General Description

Ethyl α-fluoroacetoacetate is a chemical compound with the formula C6H9O4F. It is a fluorinated derivative of acetoacetate, a key intermediate in the synthesis of various organic compounds. Ethyl α-fluoroacetoacetate is widely used as a building block in organic synthesis and serves as an important precursor for the preparation of pharmaceuticals and agrochemicals. It is also known for its reactivity in the formation of a variety of functionalized compounds, making it a valuable tool in the field of organic chemistry. Additionally, it exhibits potential applications in the development of new materials and the production of fine chemicals.

Upstream product

• 359-06-8 monofluoroacetyl chloride 
• 459-72-3 ethyl 2-fluoroacetate 
• 107-92-6 butyric acid 
• 141-78-6 ethyl acetate 
• 105-36-2 ethyl bromoacetate 
• 105-39-5 chloroacetic acid ethyl ester 

Downstream Products

• 3110-42-7 6-fluoromethyl-2-methyl-3H-pyrimidin-4-one 
• 1598-64-7 6-fluoromethyl-1H-pyrimidine-2,4-dione 
• 787-07-5 diethyl 1,4-cyclohexanedione-2,5-dicarboxylate 
• 95399-84-1 Diethyl 2,6-di-(fluoromethyl)-1,4-dihydro-4-(3-nitro-phenyl)-3,5-pyridinedicarboxylate 
• 1598-62-5 2-Thio-4-hydroxy-6-fluormethyl-pyrimidin 
• 430-51-3 1-fluoro-2-propanone 
• 1161374-53-3 ethyl 2-benzamidomethyl-4-fluoro-3-oxo-butanoate 
• 6096-27-1 4-Fluor-3-oxo-2-phenylazobuttersaeure-ethylester 
• 1598-62-5 6-fluoromethyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one 

Relevant articles and documents

INHIBITORS OF LEUCINE RICH REPEAT KINASE 2

The present invention relates to novel compounds that inhibit LRRK2 kinase activity, to processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Substituted pyridine and pyrimidine derivatives and their use in treating viral infections

The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.

SUBSTITUTED 5-METHYL-[1, 2, 4] TRIAZOLO [1,5-A) PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS

The invention provides a chemical entity of Formula (I): (I), wherein R1, R2, R3, and R4, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma- dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.